A Phase III, Multi-Center, Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Clinical Study to Evaluate Safety and Efficacy of ORADUR-Methylphenidate in Children and Adolescents With ADHD
Latest Information Update: 08 Dec 2021
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Orient Pharma
- 30 Nov 2021 Status changed from active, no longer recruiting to completed.
- 18 Sep 2018 According to a DURECT Corporation, Orient Pharma expects to have the product commercially available in Taiwan in 2019, while seeking a partner in China and pursuing regulatory approvals in selected other countries where it has commercialization rights and a commercialization presence.
- 18 Sep 2018 According to a DURECT Corporation, based on the data from this trial, Orient Pharma has obtained marketing authorization from the Ministry of Health and Welfare in Taiwan for Methydur Sustained Release Capsules, for the treatment of attention deficit hyperactivity disorder in three strengths (22 mg, 33 mg and 44 mg) in Taiwan.